We're enabling the full promise and clinical utility of ‘omic testing to deliver cost-effective care for individual patients in coordination with and context of the practical realities in today’s healthcare systems. BioClavis leverages the proprietary TempO-Seq® transcriptomic/genomic platform technology (developed by BioSpyder), capable of efficiently analyzing large cohorts with customizable biomarker panels of tens to thousands of genes, quickly and inexpensively. It has critical usability features, controls, and does not require specialized instrumentation, ideal for expansion into the clinic. These strengths--in concert with centralized patient samples, clinical research partners, and economic decision making--allow accelerating content discovery, product development and adoption of a new generation of cost-disruptive precision medicine testing worldwide.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Carus House, 201 Dumbarton Road,united Kingdom
- Phone
- +44 (0) 141 451 1328
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bioclavis.co.uk
- HQ
- Clydebank, West Dunbartonshire
Bioclavis Ltd Questions
Bioclavis Ltd's helpline number is +44 (0) 141 451 1328
Bioclavis Ltd's website is bioclavis.co.uk
Bioclavis Ltd's LinkedIn profile is https://uk.linkedin.com/company/bioclavis-ltd
Bioclavis Ltd has
12 employees.
View email and phone details for 12
employees at Bioclavis Ltd.
Bioclavis Ltd's industry is
Biotechnology Research
Bioclavis Ltd's top competitors are
Quantum Pharmaceutical Ltd,
Sygnature Discovery,
Caldan Therapeutics,
Cellular Pharmacology - Sygnature Discovery,
Amphista Therapeutics Limited,
Enterobiotix,
Biointeractions Ltd,
Causeway Therapeutics,
Roslinct,
Biospyder Technologies.
Bioclavis Ltd's categories are Biotechnology Research
Bioclavis Ltd's founding year is 2017
